Childhood diabetes towards the 21st century

Journal of Pediatric Endocrinology and Metabolism

Volumn 11, Issue 3, 1998, Pages 387-402

  Laron, Zvi ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING CARBOHYDRATE METABOLISM; ALDOSE REDUCTASE INHIBITOR; AMINOGUANIDINE; AMYLIN DERIVATIVE; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; GLUTAMATE DECARBOXYLASE; IMMUNOSUPPRESSIVE AGENT; INSULIN; NICOTINAMIDE; NITRIC OXIDE; OXYGEN RADICAL; PROTEIN TYROSINE PHOSPHATASE; ROQUINIMEX; T LYMPHOCYTE ANTIBODY;

ADOLESCENT; AUTOIMMUNITY; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DISEASE MARKER; ENVIRONMENTAL FACTOR; GENE THERAPY; HEREDITY; HUMAN; INFANT; INSULIN PUMP; INSULIN TREATMENT; INTRANASAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PANCREAS TRANSPLANTATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION; VIRUS INFECTION;

EID: 0031844912     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.1998.11.3.387     Document Type: Review

References (172)

1. Medvei VC. The History of Clinical Endocrinology, 2nd Ed. Gr Pearl River, NY: Pantheon Publ., 1993; 9 and 35.
2. Johnston DT. Diabetes: Definition and Classifications. In: Kelnar CJH, ed. Childhood and Adolescent Diabetes. London: Chapman & Hall, 1995; 135-138.
3. Glaser NS. Non-insulin-dependent diabetes mellitus in childhood and adolescence. Pediatr Clin N Am 1997; 44: 307-323.
4. Scott CR, Smith JM, Cradock MM, Pihoker C. Characteristics of youth-onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. Pediatrics 1997; 100:84-89.
5. Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr 1994; 83: 849-853
6. Fukui M, Nakano K, Obayashi H, Kitagawa Y, Nakamura N, Mori H, Kajiyama S, Wada S, Fujii M, Yoshimori K, Kanaitsuka T, Shigeta H, Kondo M. High prevalence of mitochondrial diabetes mellitus in Japanese patients with major risk factors. Metabolism 1997; 46: 793-795.
7. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996; 39: 1005-1029.
8. Bosi E, Sarugeri E. Advances and controversies in etiopathogenesis of type 1 (insulin-dependent) diabetes mellitus. J Pediatr Endocrinol Metab 1998; 11 (Suppl. 2): 293-305.
9. Todd JA. The role of MHC class II genes in type 1 diabetes. Curr Topics Microb Immunol 1990; 164: 17-40.
10. Thorsby E, Undlien D. The HLA associated predisposition to type 1 diabetes and other autoimmune diseases. J Pediatr Endocrinol Metab 1996; 9 (Suppl.1): 75-78.
11. Khalil H, D'Auriol L, Gobet M, Morin L, Lepage V, Deschamps I, Park MS, Degos L, Galibert F, Hors J. A combination of HLA-DQβ Asp 57-negative and HLA-DQα Arg 52 confers susceptibility to insulin-dependent diabetes mellitus. J Clin Invest 1990; 85: 1315-1319.
12. Davies JL, Kawaguchi Y, Bennet ST, Copeman JB, Cordell HJ, Pritchard LE, Reed PW, Gough SCL, Jenkins SC, Palmer SM, Balfour KM, Rowe BR, Farral M, Barnett AH, Bain SC, Todd JA. A genome-wide search for human type 1 diabetes susceptibility genes. Nature 1994; 371: 130-136.
13. Undlien DE, Akselsen HE, Joner G, Dahl-Jorgensen K, Aagenaes O, Sovik O, Thorsby E, Ronningen KS. No difference in the parental origin of susceptibility HLA class II haplotypes among Norwegian patients with insulin-dependent diabetes mellitus. Letter to the Editor. Am J Hum Genet 1995; 57: 1511-1514.
14. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furata H, Vaxillaire M, Southam L, Cox RD, Lathrop M, Boriraj VV, Chen X, Cox NJ, Oda Y, Yano H, Le Beau MM, Yamada S, Nishigori H, Takeda Y, Fajans SS, Hattersley AT, Iwasaki N, Hansen T, Pedersen O, Polonsky KS, Turner RC, Velho G, Chevre JC, Froguel P, Bell GI. Mutations in the hepatocyte nuclear factor I gene in maturity-onset diabetes of the young (MODY 3). Nature 1996; 384: 455-458.
15. Gerbitz KD, Gempel K, Brdiczka D. Perspectives in diabetes, mitochondrial and diabetes. Genetic, biochemical, and clinical implications of the cellular energy circuit. Diabetes 1996; 45: 113-126.
16. Ballinger SW, Shoffner JM, Hedaya EV, Trounce I, Polak MA, Koontz DA, Wallace DC. Maternally transmitted diabetes and deafness associated with a 10.4kb mitochondrial DNA deletion. Nature Genet 1992; 1: 11-15.
17. Hofmann S, Bezold R, Jaksch M, Kaufhold P, Obermaier-Kusser B, Gerbitz KD. Analysis of the mitochondrial DNA from patients with Wolfram (DID-MOAD) syndrome. Mol Cell Biochem 1997; 174: 209-213.
18. Rewers M, Bugawan TL, Morris JM, Blair A, Beaty B, Hoffman M, McDuffie RS Jr, Hamman RF, Klingensmith G, Eisenbarth GS, Erlich HA. Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 1996; 39: 807-812.
19. Falorni A, Lemmark A. Humoral autoimmunity. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus, Chapter 31. Philadelphia: Lippincott-Raven Publ., 1996; 298-307.
20. Landin-Olsson M, Palmer JP, Lernmark A, Blom L, Sundkvist G, Nystrom L, Dahlquist G. Predicitive value of islet cell and insulin autoantibodies for type 1 (insulin-dependent) diabetes mellitus in a populationbased study of newly-diagnosed and matched control children. Diabetologia 1992; 35: 1068-1073.
21. Kuglin B, Kolb H, Greenbaum C, Maclaren NK, Lernmark A, Palmer JP. The Fourth International Workshop on the Standardisation of Insulin Autoantibody Measurement. Diabetologia 1990; 33: 638-639.
22. Vandewalle CL, Falorni A, Svanholm S, Lemmark A, Pipeleers DG, Gorus FK. Belgian Diabetes Registry. High diagnostic sensitivity of glutamate decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years. J Clin Endocrinol Metab 1995; 80: 846-851.
23. Gorus FK, Goubert P, Semakula C, Vandewalle CL, De Schepper J, Schee A, Christie MR, Pipeleers DG, Belgian Diabetes Registry. IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. Diabetologia 1997; 40: 95-99.
24. Kasuga A, Maruyama T, Ozawa Y, Takei I, Falorni A, Lemmark A, Saruta T. Antibody to the Mr 65,000 isoform of glutamic acid decarboxylase are detected in non-insulin dependent diabetes in Japanese. J Autoimmunity 1996; 9: 105-111.
25. Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in Stoff-Man syndrome. N Engl J Med 1990; 322: 1555-1560.
26. Tuomi T, Bjorses PL, Falomi A, Partanen J, Perheentupa J, Lernmark A, Miettinen A. Antibodies to glutamic acid decarboxylase and insulin-dependent diabetes in patients with APS 1 (autoimmune polyendocrine syndrome type 1). J Clin Endocrinol Metab 1996; 81: 1488-1494.
27. Hallengren B, Falorni A, Landin-Olsson M, Lernmark A, Papadopoulous KI, Sundkvist G. Islet cell and glutamic acid decarboxylase antibodies in hyperthyroid patients - at diagnosis and following treatment. J Intern Med 1996; 239: 63-68.
28. Bingley PJ, Christie MR, Bonifacio E, Bonfanti R, Shattock M, Fonte MT, Bottazzo GF, Gale EAM. Combined analysis of IDDM-related autoantibodies improves prediction of IDDM in islet cell antibody positive relatives. Diabetes 1994; 43: 1304-1310.
29. Vahasalo P, Knip M, Karjalainen J, Tuomilehto-Wolf E, Lounamaa R, Akerblom HK and the Childhood Diabetes in Finland Study Group. Islet cell-specific autoantibodies in children with insulin-dependent diabetes mellitus and their siblings at clinical manifestation of the disease. Eur J Endocrinol 1996; 135: 689-695.
30. Falorni A, Kassi G, Murdolo G, Calcinaro F. Controversies on humoral immune markers of insulin-dependent diabetes mellitus. J Pediat Endocrinol Metab 1998; 11 (Suppl. 2): 307-317.
31. LaPorte RE, Tajima N, Akerblom HK, Berlin N, Brosseau J, Christy M, Drash AL, Fishbein H, Green A, Hamman R, Harris M, King H, Laron Z, Neil A. Geographic differences in the risk of insulin-dependent diabetes mellitus: the importance of registries. Diabetes Care 1985; 8 (Suppl.1): 101-107.
32. Green A, Gale EAM, Patterson GC for the Eurodiab ACE Study Group. Incidence of childhood-onset insulin-dependent diabetes mellitus; the Eurodiab ACE study. Lancet 1992; 339: 905-909.
33. WHO DIAMOND Project: WHO multinational project for childhood diabetes. Diabetes Care 1990; 13: 1062-1068.
34. Eurodiab ACE-Collaborative Study Final Report 1989-1996. In preparation.
35. Songini M. Epidemiology of IDDM. In: Laron Z, Pinelli L, eds. Progress on Childhood Diabetes, Cosenza, Italy: Editoriale Bios, 1997; 29-40.
36. Bingley PJ, Gale EAM. Rising incidence of IDDM in Europe. Diabetes Care 1989; 23: P289-295.
37. Joner G, Sovik O. Increasing incidence of diabetes mellitus in Norwegian children 0-14 years of age 1973-1982. Diabetologia 1989; 32: 79-83.
38. Tuomilehto-Wolf E, Åkerblom HK. Increasing trend in type 1 (insulin dependent) diabetes mellitus in childhood in Finland. Diabetologia 1991; 34: 282-287.
39. Soltesz G, Madacsy L, Bekefi D, Danko J. Hungarian Childhood Diabetes Epidemiology Group: Rising incidence of type 1 diabetes in Hungarian children. Diabetic Med 1990; 7: 111-114.
40. Drykoningen CEM, Mulder AL, Vaandrager FJ, LaPorte RE, Bruining GJ. The incidence of male childhood type 1 (insulin-dependent) diabetes mellitus is rising rapidly in The Netherlands. Diabetologia 1992; 35: 139-142.
41. Schober E, Schneider U, Waldhor T, Tuomilehto J, the Austrian Diabetes Incidence Study Group. Increasing incidence of IDDM in Austrian children: a nationwide study 1979-1993. Diabetes Care 1995; 18: 1280-1283.
42. Shamis I, Gordon O, Albag Y, Goldsand G, Laron Z. Ethnic differences in the incidence of childhood IDDM in Israel (1965-1993). Marked increase since 1985, especially in Yemenite Jews. Diabetes Care 1997; 20: 504-508.
43. Samanta A, Burden AC, Jones GR, Woollands IG, Clarke M, Swift PGF, Hearnshaw JR. Prevalence of insulin-dependent diabetes mellitus in Asian children. Diabetic Med 1987; 4: 65-67.
44. Karam J, Lewitt P, Young C, Nowlain RE, Frankel BJ, Fujiya H, Freedman ZD, Grodsky GM. Insulinopenic diabetes after rodenticide (VACOR) ingestion: a unique model of acquired diabetes in man. Diabetes 1980; 29: 971-978.
45. Helgason T, Jonasson MR. Evidence for a food additive as a cause of ketosis-prone diabetes. Lancet 1981; 2: 716-720.
46. Scott FW. Cow milk and insulin-dependent diabetes mellitus: Is there a relationship? Am J Clin Nutr 1990; 51:489-491.
47. Borch-Johnsen K, Mandrup-Poulsen T, Zachau-Christiansen B, Jonen G, Christy M, Kastrup K. Relationship between breast feeding and incidence rates of insulin dependent diabetes melletus. Lancet 1984; 2: 1083-1086.
48. Elliott RB, Martin JM. Dietary protein: a trigger of insulin-dependent diabetes in the BB rat? Diabetologia 1984; 26: 297-299.
49. Gerstein HC. Cow's milk exposure and type I diabetes mellitus. Diabetes Care 1994; 17: 13-18.
50. Åkerblom HK, Savilahti E, Saukkonen TT, Paganus A, Virtanen SM, Teramo K, Knip M, Ilonen J, Reijonen H, Karjalainen J, Vaarala O, Reunanen A. The case for elimination of cow's milk in early infancy in the prevention of type 1 diabetes: The Finnish experience. Diab Metab Rev 1993; 9: 269-278.
51. Fuchtenbusch M, Karges W, Standl E, Dosch HM, Ziegler AG. Antibodies to bovine serum albumin (BSA) in type 1 diabetes and other autoimmune disorders. Exp Clin Endocrinol Diab 1997; 105: 86-91.
52. Akerblom HK, Vaarala O. Cow milk proteins, autoimmunity and type 1 diabetes. Exp Clin Endocrinol Diab 1997; 105: 83-85.
53. Pettitt DJ, Forman MR, Hanson RL, Knowler WC, Bennett PH. Breastfeeding and incidence of non-insulin-dependent diabetes mellitus in Pima Indians. Lancet 1997; 350: 166-168.
54. Parslow RC, McKinney PA, Law GR, Staines A, Williams R, Bodansky HJ. Incidence of childhood diabetes mellitus in Yorkshire, Northern England, is associated with nitrate in drinking water: an ecological analysis. Diabetologia 1997; 40: 550-556.
55. Manz F. Residues of pesticides in baby food. Int Child Hlth 1996; 7: 3-11.
56. Yoon JW. A new look at viruses in type I diabetes. Diab Metab Rev 1995; 11: 83-107.
57. Yoon JW, Austin M, Onodera T, Notkins AL. Virusinduced diabetes mellitus: Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 1979; 300: 1173-1179.
58. Clements GA, Galbraith DN, Taylor KW. Coxsackie B virus and onset of childhood diabetes. Lancet 1995; 346: 221-223.
59. Hyoty H, Hiltunen M, Knip M, Laakkonen M, Vahasalo P, Kaijalainen J, Koskela P, Roivainen M, Leinikki P, Hovi T, Akerblom HK, the Childhood Diabetes in Finland (DIME) Study Group. A prospective study of the role of Coxsackie B and other enterovirus infections in the pathogenesis of IDDM. Diabetes 1995; 44: 652-657.
60. Dahlquist G, Ivarsson S, Lindberg B, Forsgren M. Maternal enteroviral infection during pregnancy as a risk factor for childhood IDDM. A population-based case-control study. Diabetes 1995; 44: 408-413.
61. Kaufman DL, Erlander MG, Clare-Saizler M, Atkinson MA, McClaren NK, Tobin AJ. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 1992; 89: 382-392.
62. Baum H, Brusic V, Choudhuri K, Cunningham P, Vergani D, Peakman M. MHC molecular mimicry in diabetes. Nature Med 1995; 1: 388.
63. Graves PM, Norris JM, Pallansch MA, Gerling IC, Rewers M. The role of enteroviral infections in the development of IDDM. Limitations of current approaches. Diabetes 1997; 46: 161-168.
64. Conrad B, Weissmahr RN, Boni J, Arcari R, Schupbach J, Mach B. A human endogenous retroviral superantigen as candidate autoimmune gene in type 1 diabetes. Cell 1997; 90: 303-313.
65. Rothwell PM, Staines A, Smail P, Wadsworth E, McKinney P. Seasonality of birth of patients with childhood diabetes in Britain. BMJ 1996; 312: 1456-1457.
66. Laron Z, Shamis I, Ashkenazi I. Inverse relationship between month of birth and month of onset of IDDM in Jewish children in Israel. Diabetes 1998; Suppl (in press).
67. Law GR, McKinney PA, Staines A, Williams R, Kelly M, Alexander F, Gilman E, Bodansky HJ. Clustering of childhood IDDM. Links with age and place of residence. Diabetes Care 1997; 20: 753-756.
68. Patterson CC, Carson DJ, Hadden DR on behalf of the Northern Ireland Diabetes Study Group. Epidemiology of childhood IDDM in Northern Ireland 1989-1994: Low incidence in areas with highest population density and most household crowding. Diabetologia 1996; 39: 1063-1069.
69. Welsh N, Eizirik DL, Sandler S. Nitric oxide and pancreatic β-cell destruction in insulin dependent diabetes mellitus: don't take no for an answer. Autoimmunity 1994; 18: 285-290.
70. Curcio F, Ceriello A. Decreased cultured endothelial cell proliferation in high glucose medium is reversed by antioxidants: new insights on the pathophysiological mechanisms of diabetic vascular complications. In Vitro Cell Dev Biol 1992; 28A: 787-790.
71. Kurz S, Garrison DG. Insulin and the arginine paradox. (Editorial). J Clin Invest 1997; 99: 369-370.
72. Kolb H, Hiesel U, Kroncke K-D, Kolb-Bachofen V. Suppression of low dose streptozotocin induced diabetes in mice by administration of a nitric oxide synthase inhibitor. Life Sci 1991; 49: PL213-217.
73. Hammes HP, Bartmann A, Engel L, Wulfroth P. Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine. Diabetologia 1997; 40: 629-634.
74. Biesalski HK, Bohles H, Esterbauer H, Furst P, Gey F, Hundsdorfer G, Kasper H, Sies H, Weissburger J. Antioxidant vitamins in prevention. Clin Nutr 1997; 16: 151-155.
75. Komulainen J, Lounamaa R, Knip M, Kaprio EA, Åkerblom HK, and the Childhood Diabetes in Finland Study Group. Ketoacidosis at the diagnosis of type 1 (insulin dependent) diabetes mellitus is related to poor residual β cell function. Arch Dis Child 1996; 75: 410-415.
76. ISPAD/IDF-Europe/WHO-Europe. Consensus Guidelines for the Management of Insulin-Dependent (Type 1) Diabetes Mellitus (IDDM) in Childhood and Adolescence. Laron Z, Swift P, Silink M, eds, for ISPAD. Tel Aviv-London: Freund Publishing House, 1995; pp. 42.
77. Ramos O, personal communication.
78. Mauras N, Merimee T, Rogol AD. Function of the growth hormone-insulin-like growth factor-I axis in the profoundly growth-retarded diabetic child: Evidence for defective target organ responsiveness in the Mauriac syndrome. Metabolism 1991; 40: 1106-1111.
79. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
80. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994; 125: 177-188.
81. Brinchnann-Hanson O, Dahl-Jorgensen K, Hanssen KF, Sandvik L. The response of diabetic retinopathy to 41 months of multiple insulin injections, insulin pumps, and conventional insulin therapy. Arch Ophthalmol 1988; 106: 1242-1246.
82. Holleman F, Hoekstra JBL. Insulin lispro. N Engl J Med 1997; 337: 176-183.
83. Brange J. The new era of biotech insulin analogues. Diabetologia 1997; 40: S48-S53.
84. Bolli GB. Counterregulatory mechanisms to insulin-induced hypoglycemia in humans: relevance to the problem of intensive treatment of IDDM. J Pediatr Endocrinol Metab 1998; 11 (Suppl 1): 103-115.
85. Mortensen HB, Hougaard P, for the Hvidøre Study Group on Childhood Diabetes. Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries. Diabetes Care 1997; 20: 714-720.
86. Dorchy H, Olinger S. Bien-etre des diabetiques insulino-dependants. Evaluation chez 100 adolescents et adultes jeunes en fonction de leur controle metabolique. La Presse Med 1997; 26: 1420-1424.
87. Kalter-Leibovici O, Laron Z. Vascular complications of childhood diabetes mellitus. Curr Opin Pediatr 1992; 4: 685-694.
88. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328: 1676-1684.
89. Kalter-Leibovici O, Van Dyk DJ, Leibovici L, Loya N, Erman A, Kremer I, Boner G, Rosenfeld JB, Karp M, Laron Z. Risk factors for development of diabetic nephropathy and retinopathy in Jewish IDDM patients. Diabetes 1991; 40: 204-210.
90. Quinn M, Angelico MC, Warram JH, Krolewski AS. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 1996; 39: 940-945.
91. Donaghue KC, Fairchild JM, Chan A, Hing SJ, King J, Howard NJ, Silink M. Diabetes microvascular complications in prepubertal children. J Pediatr Endocrinol Metab 1997; 10: 579-585.
92. Danne T, Kordonouri O. Controversies on the pathogenesis of diabetic angiopathy: which treatment for normotensive adolescents with microalbuminuria and type 1 diabetes? J Pediatr Endocrinol Metab 1998; 11 (Suppl 2): 347-363.
93. Feener EP, King GL. Vascular dysfunction in diabetes mellitus. Lancet 1997; 350 (Suppl 1): 9-13.
94. DERI Mortality Study Group. Sex differences in the mortality associated with insulin-dependent diabetes mellitus in four countries. The Diabetes Epidemiology Research International (DERI) Study. Am J Epidemiol 1991; 133: 577-584.
95. Icks A, Trautner C, Haastert B, Berger M, Giani G. Blindness due to diabetes: Population-based age and sex-specific incidence rates. Diabetic Med 1997; 14: 571-575.
96. Shichiri M, Yamasaki Y, Kawamori R, Hakui N, Abe H. Wearable artificial pancreas with needle-type glucose sensor. Lancet 1982; 2: 1129-1131.
97. Lassmann-Vague V, Guerci B, Hanaire-Broutin H, Pinget M, Renard E, Selam J-L, Vague P, pour le groupe EVADIAC. Utilisation des pompes a insuline implantables: La position d'EVADIAC. Diabete Metab 1997; 23: 242-250.
98. Jaremko J, Rorstad O. Advances toward the implantable artificial pancreas for treatment of diabetes. Diabetes Care 1998; 21: 444-450.
99. Ng Tang Gui S, Pickup JC, Bending JJ, Collins ACG, Keen H, Dalton N. Hypoglycemia and counterregulation in insulin-dependent diabetic patients: a comparison of continuous subcutaneous insulin infusion and conventional insulin injection therapy. Diabetes Care 1986; 9: 221-227.
100. Prendergast JJ, Donsey C, Elsea V. Over-delivery of insulin by insulin pumps. Diabetes Care 1995; 18: 1201-1202.
101. Chantelau E, Lange G, Sonnenberg GE, Berger M. Acute cutaneous complications and catheter needle colonization during insulin-pump treatment. Diabetes Care 1987; 10: 478-482.
102. Saffian M, Kumar GS, Savariar C, Bumham JC, Williams F, Neckers DC. A new approach to the oral administration of insulin and other peptide drugs. Science 1986; 233: 1081-1084.
103. Bruce DG, Chrisolm DJ, Stonlien LH, Bunkman M, Kraegen EW. Meal-time intranasal insulin delivery in type 1 diabetes. Diabetic Med 1991; 8: 366-370.
104. Mitragotri S, Blanckschtein D, Langer R. Ultrasoundmediated transdermal protein delivery. Science 1995; 269: 850-853.
105. Young AA. Amylin regulation of fuel metabolism. J Cell Biochem 1994; 55 (Suppl): 12-18.
106. Kolterman OG, Schwartz S, Conder C, Levy B, Klaff L, Peterson J, Gottlieb A. Effects of 14 days subcutaneous administration of the human amylin analogue, premlinticle (AC 137) on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 1996; 39: 492-499.
107. Stewart C, Taylor NA, Docherty K, Bailey CJ. Insulin delivery by somatic cell gene therapy. J Mol Endocrinol 1993; 11: 335-341.
108. Assan R, Clauser E, Larger E. Une therapie genique des syndromes diabetiques est-elle envisageable? Diabete Metab 1994; 20: 240-250.
109. Kolodka TM, Finegold M, Moss L, Woo SLC. Gene therapy for diabetes mellitus in rats by hepatic expression of insulin. Proc Natl Acad Sci USA 1995; 92: 3293-3297.
110. Calafiore R. Perspectives in pancreatic and islet cell transplantation for the therapy of IDDM. Diabetes Care 1997; 20: 889-896.
111. Stratta RJ, Larsen JL, Cushing RN. Pancreas transplantation for diabetes mellitus. Ann Rev Med 1995; 46: 281-298.
112. Secchi A, Socci C, Maffi P, Taglietti MV, Lalqui L, Bertuzzi F, De Nittis P, Piemonti L, Scopsi L, Di Carlo V, Pozza G. Islet transplantation in IDDM patients. Diabetologia 1997; 40: 225-231.
113. Alejandro R, Angelico MC, Ricordi C, Burke G, Nery J, Miller J, Esquenazi V, Mintz DH. More than 5-year islet allograft function in insulin-dependent diabetes mellitus. Transplant Proc 1997; 29: 2229-2230.
114. Luzi L, Hering BJ, Socci C, Raptis G, Battezzati A, Terruzzi I, Falqui L, Brandhorst H, Brandhorst D, Regalia E, Brambilla E, Secchi A, Perseghin G, Maffi P, Bianchi E, Mazzaferro V, Gennari L, Di Carlo V, Federlin K, Pozza G, Bretzel RG. Metabolic effects of successful intraportal islet transplantation in insulindependent diabetes mellitus. J Clin Invest 1996; 97: 2611-2618.
115. Weir GC, Bonner-Weir S. Islet transplantation: Why is it taking so long? Diab Rev Int 1997; 6: 2-5.
116. Groth CG, Korsgren O, Tibell A, Tollemar J, Moller E, Bolinder J, Ostman J, Reinholt FP, Hellerstrom C, Andersson A. Transplantation of porcine fetal pancreas to diabetic patients. Lancet 1994; 344: 1402-1404.
117. Sun Y, Xiaojun M, Daobiao Z, Vacek I, Sun AM. Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J Clin Invest 1996; 98: 6: 1417-1422.
118. Financial Times, Sept 13-14, 1997; 7.
119. Calafiore R, Barta G, Osticioli L, Luca G, Tortoioli C, Brunetti P. Coherent microcapsules for pancreatic islet transplantation: a new potential approach for bioartificial pancreas. Transplant Proc 1995; 28: 822-823.
120. Suzuki K, Bonner-Weir S, Hollister J, Weir GC. A method for estimating number and mass of islets transplanted within a membrane device. Cell Transplant 1996; 5: 613-625.
121. Newgard CB, Clark S, BeltrandeRio H, Hohmeier HE, Quaade C, Normington K. Engineered cell lines for insulin replacement in diabetes: current status and future prospects. Diabetologia 1997; 40: S42-S47.
122. Greene DA, Lattimer SA, Sima AAF. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987; 316: 599-606.
123. Clark CM, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995; 332: 1210-1217.
124. Brownlee M. Glycation and diabetic complications. Diabetes 1994; 43: 836-846.
125. Aiello LP. Vascular endothelial growth factor. Invest Ophthalmol Visual Sci 1997; 38: 1647-1652.
126. Paques M, Massin P, Gaudric A. Growth factors and diabetic retinopathy. Diabete Metab (Paris) 1997; 23: 125-130.
127. Laron Z, Karp M, eds. Prediabetes - Are we Ready to Intervene? Pediatr Adolesc Endocrinol. Basel: Karger 1993; 23: pp 188.
128. Zinman B. Diabetes research: Are we getting anywhere? Can Med Assoc J 1996; 155: 1271-1274.
129. Skyler JS, Marks JB. Immune intervention in type I diabetes mellitus. Diab Rev 1993; 1: 15-42.
130. Bougnères PF, Landais P, Boisson C, Carel JC, Frament N, Boitard C, Chaussain JL, Bach JF. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporine. Diabetes 1990; 39: 1264-1272.
131. Assan R, Feutren G, Sirmai, J, Laborie C, Boitard C, Vexiau P, Du Rosto H, Rodier M, Figoni M, Vague P. Plasma C-peptide levels and clinical remission in recent-onset type 1 diabetic patients treated with axathioprine. Diabetes 1990; 39: 768-774.
132. Martin S, Schemthaner G, Nerup J, Gries FA, Koivisto VA, Dupre J, Standl E, Hamet P, McArthur R, Tan MH, Dawson K, Mehta AE, Van Vliet S, von Graffenried B, Stiller C, Kolb H. Follow-up of cyclosporin A treatment in type I (insulin dependent) diabetes mellitus: lack of long-term effects. Diabetologia 1991; 34: 429-434.
133. Bengtsson M, Simonsson B, Carlsson K, Nielsson B, Smedmyr B, Temander B, Oberg G, Totterman Th. Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia. Transplantation 1992; 53: 882-888.
134. Gross DJ, Sidi H, Weiss L, Kalland T, Rosenmann E, Slavin S. Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug. Diabetologia 1994; 37: 1195-1201.
135. Visalli N, Boccuni ML, Baroni MG, Buzzetti R, Nistico L, Fioriti E, Mesturino C, Signore A, Cavallo MG, Andreani D, Lucentini L, Matteoli MC, Crino A, Cicconetti CA, Teodonio C, Amoretti R, Paci F, Ruggeri M, Pisano L, Pennafina MG, Suraci C, Santopadre G, Boscherini B, Stoduto S, Fonte MT, Batelli F, Multari G, Campea L, Suppa MA, De Mattia GC, Cassone Faldetta M, Marozzi G, Mancini A, Testa G, Marietti G, Ponte E, Perrone F, Bizzari C, Greco AV, Ghirlanda G, Pozzilli M (the IMDIAB Group). BCG vaccine and nicotinamide in recent onset IDDM: a randomized multicenter study. (Abstract A278). Autoimmunity 1995; 21:73.
136. Dulin WE, Wyse BM, Kalamazoo MS. Studies on the ability of compounds to block the diabetogenic activity of streptozotocin. Diabetes 1969; 18: 459-466.
137. Nomikos IN, Prowse SJ, Carotenuto P, Lafferty KJ. Combined treatment with nicotinamide and desferrioxamine prevents islet allografts destruction in NOD mice. Diabetes 1986; 35: 1302-1304.
138. Gale EAM. Theory and practice of nicotinamide trials in pre-type 1 diabetes. J Pediatr Endocrinol Metab 1996; 9: 375-379.
139. Greenbaum CJ, Kahn SE, Palmer JP. Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM. Diabetes 1996; 45: 1631-1634.
140. Peakman M, Hussain MJU, Millward BA, Leslie RD, Vergani D. Effect of initiation of insulin therapy on T-lymphocyte activation in type 1 diabetes. Diabetic Med 1990; 7: 327-330.
141. Shah SC, Malone IL, Simpson NE. A randomized trial of intensive therapy in newly diagnosed insulin-dependent diabetes mellitus, N Engl J Med 1989; 320: 550-554.
142. Schnell O, Eisfelder B, Standl E, Ziegler AG. Highdose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM. Diabetes 1997; 46: 1607-1611.
143. DPTI-I Study Group. The Diabetes Prevention Trial-Type-1 diabetes (DPT-I): implementation of screening and staging of relatives. Transplant Proc 1995; 27: 3377.
144. Knip M, Åkerblom HK. IDDM prevention trials in progress - A critical assessment. J Pediatr Endocrinol Metab 1998; 11 (Suppl 2): 371-377.
145. Komulainen J, Knip M, Lounamaa R, Vahasalo P, Karjalainen J, Sabbah E, Åkerblom HK, and the Childhood Diabetes in Finland Study Group. Poor betacell function after the clinical manifestation of type 1 diabetes in children initially positive for islet cell specific autoantibodies. Diabetic Med 1997; 14: 532-537.
146. Elliott RB, Pilcher CC, Fergusson DM, Stewart AW. A population based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab 1996; 9: 501-509.
147. Ludvigsson J. Ethical aspects on clinical studies of prediabetes. In: Laron Z, Karp M, eds. Prediabetes - Are we Ready to Intervene? Pediatr Adolesc Endocrinol. Basel: Karger 1993; 23: 175-179.
148. Nordenfeldt L. Prevention and ethics in medicine: The case of diabetes prevention. J Pediatr Endocrinol Metab 1996; 9: 381-386.
149. Brink SJ, Grossman HY. Gazing into the future: Initial psychosocial assessment of a prediabetes detection program. In: Laron Z, Karp M, eds. Prediabetes - Are we Ready to Intervene? Pediatr Adolesc Endocrinol. Basel: Karger 1993; 23: 157-164.
150. Guthrie DW. Parents' and siblings' response to prediabetes. In: Laron Z, Karp M, eds. Prediabetes - Are we Ready to Intervene? Pediatr Adolesc Endocrinol. Basel: Karger 1993; 23: 165-170.
151. Galatzer A, Green E, Ofan R, Ben-Zaken H, Josefsberg Z, Weintrob N, Karp M, Vardi P. Psychological impact of islet cell antibody screening (Abstract). Acta Diabetol 1998; 35 (Suppl 1): S4.
152. Surwit RS, Schneider MS. Role of stress in the etiology and treatment of diabetes mellitus. Psychosom Med 1993; 55: 380-383.
153. Åkerblom HK. Diabetes and cow's milk (Letter). Lancet 1996; 348: 1656-1657.
154. Laron Z. Psycho-social problems of diabetic children and adolescents. Acta Diabetol Latina 1984; 21: 35-46.
155. Laron Z, Galatzer A, eds. Psychological Aspects of Diabetes in Children and Adolescents. Pediatr Adolesc Endocrinol. Basel: Karger 1982; 10: pp 247.
156. Laron Z, Galatzer A, eds. Recent Progress in Medico-Social Problems in Juvenile Diabetics. Pediatr Adolesc Endocrinol. Basel: Karger 1983; 11: pp 209.
157. Laron Z, Galatzer A, Amir S, Gil R, Karp M, Mimouni M. A multidisciplinary comprehensive, ambulatory treatment scheme for diabetes mellitus in children. Diabetes Care 1979; 2: 342-348.
158. Galatzer A, Amir S, Gil R, Karp M, Laron Z. Crisis intervention program in newly diagnosed diabetic children. Diabetes Care 1982; 5: 414-419.
159. La Greca AM, Auslander WF, Greco P, Spetter D, Fisher EB Jr, Santiago JV. I get by with a little help from my family and friends: Adolescents' support for diabetes care. J Pediatr Psychol 1995; 20: 449-476.
160. Laron Z. School, work, driving and insurance for the diabetic. In: Larkins R, Zimmet P, Chisholm D, eds. The Diabetic in Society - Living with Diabetes. Amsterdam: Elsevier Science Publ. BV 1989; 881-886.
161. Petrides P. Discrimination of juvenile diabetics in various professions. In: Laron Z, Galatzer A, eds. Recent Progress in Medico-Social Problems in Juvenile Diabetics. Pediatr Adolesc Endocrinol: Basel: Karger 1983; 11: 50-53.
162. Pereg M. Insurance of diabetics. In: Laron Z, Karp M, eds. Prediabetes - Are we Ready to Intervene? Pediatr Adolesc Endocrinol. Basel: Karger 1993; 23: 184-186.
163. Kovacs M, Goldston D, Obrosky DS, Bonar LK. Psychiatric disorders in youths with IDDM. Rates and risk factors. Diabetes Care 1997; 20: 36-44.
164. Gray AM, Fenn P, McGuire A. The cost of insulin dependent diabetes mellitus (IDDM) in England and Wales. Diabetic Med 1995; 12: 1068-1076.
165. Javor KA, Kotsanos JG, Baron A, Kesterson J, Tierney W, McDonald R. Diabetic ketoacidosis costs relative to medical costs of patients with type I diabetes. Pharmacoepidemiol Drug Safety 1996; 5 (Suppl 1): S15.
166. Rathmann W, Haastert B, Delling B, Roseman JM, Giani G, Gries FA. Prescription drug use and costs among patients with diabetes mellitus. Pharmacoepidemiol Drug Safety 1996; 5 (Suppl 1): S20.
167. Todd C. Adding up the economic cost of treating diabetes mellitus. Inpharma 1996; 1057: 9-10.
168. Ratner RE. Long-term health care outcomes in diabetes. Endocrinol Metab Clin N Am 1997; 26: 487-498.
169. ISPAD Declaration of Kos. In: ISPAD/IDF-Europe/ WHO-Europe. Consensus Guidelines for the Management of Insulin-Dependent (Type I) Diabetes Mellitus (IDDM) in Childhood and Adolescence. Laron Z, Swift P, Silink M, eds. for ISPAD. Tel Aviv-London: Freund Publishing House; 1995: 10.
170. Laron Z, Flexer Z, Albag Y, Ofan R. The use of computers in the control of diabetes in children and adolescents. J Endocrinol Invest 1989; 12 (Suppl 3): 113-120.
171. Azzopardi J, Fenech FF, Junoussov Z, Mazovetsky A, Olchanski V. A computerized health screening and follow-up system in diabetes mellitus. Diabetic Med 1995; 12: 271-276.
172. Miyasaka K, Suzuki Y, Sakai H, Kondo Y. Interactive communication in high-technology home care: Videophones for pediatric ventilatory care. Pediatrics 1997; 99: 1-6.